Abiomed Inc.
48
6
16
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.7%
8 terminated/withdrawn out of 48 trials
65.2%
-21.3% vs industry average
8%
4 trials in Phase 3/4
20%
3 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (48)
Platelet Function and Impella Support
Role: collaborator
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
Role: lead
Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock
Role: collaborator
Impella ECP Early Feasibility Study
Role: lead
Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Role: lead
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
Role: lead
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
Role: lead
Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol
Role: lead
PPCM Observational Study (Peripartum Cardiomyopathy)
Role: collaborator
Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study
Role: lead
Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps
Role: lead
Abiomed Impella RT-DAQ - Observational Study
Role: lead
IMPACT EU Post-Market Clinical Follow-Up Study
Role: lead
SVC Occlusion in Subjects With Acute Decompensated Heart Failure
Role: lead
Impella Reverse Remodeling in End-Stage Heart Failure
Role: collaborator
IMpella-Protected cArdiaC Surgery Trial (IMPACT)
Role: lead
V-A ECMO AUTO Mode Registry
Role: lead
National Cardiogenic Shock Initiative
Role: collaborator
Cardiogenic Shock Working Group Registry
Role: collaborator
SURPASS Impella 5.5 Study
Role: lead